198 related articles for article (PubMed ID: 31732842)
21. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
[TBL] [Abstract][Full Text] [Related]
22. Integrated transcriptomic and metabolomic analysis shows that disturbances in metabolism of tumor cells contribute to poor survival of RCC patients.
Popławski P; Tohge T; Bogusławska J; Rybicka B; Tański Z; Treviño V; Fernie AR; Piekiełko-Witkowska A
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):744-752. PubMed ID: 28012969
[TBL] [Abstract][Full Text] [Related]
23. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
[TBL] [Abstract][Full Text] [Related]
24. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
26. Pathway analysis of kidney cancer using proteomics and metabolic profiling.
Perroud B; Lee J; Valkova N; Dhirapong A; Lin PY; Fiehn O; Kültz D; Weiss RH
Mol Cancer; 2006 Nov; 5():64. PubMed ID: 17123452
[TBL] [Abstract][Full Text] [Related]
27. Differential protein profiling of renal cell carcinoma urinary exosomes.
Raimondo F; Morosi L; Corbetta S; Chinello C; Brambilla P; Della Mina P; Villa A; Albo G; Battaglia C; Bosari S; Magni F; Pitto M
Mol Biosyst; 2013 Jun; 9(6):1220-33. PubMed ID: 23511837
[TBL] [Abstract][Full Text] [Related]
28. Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.
Bifarin OO; Gaul DA; Sah S; Arnold RS; Ogan K; Master VA; Roberts DL; Bergquist SH; Petros JA; Fernández FM; Edison AS
J Proteome Res; 2021 Jul; 20(7):3629-3641. PubMed ID: 34161092
[TBL] [Abstract][Full Text] [Related]
29. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
30. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
31. Application of ex vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases.
Gao H; Dong B; Jia J; Zhu H; Diao C; Yan Z; Huang Y; Li X
J Cancer Res Clin Oncol; 2012 May; 138(5):753-61. PubMed ID: 22258851
[TBL] [Abstract][Full Text] [Related]
32. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis.
Wettersten HI; Hakimi AA; Morin D; Bianchi C; Johnstone ME; Donohoe DR; Trott JF; Aboud OA; Stirdivant S; Neri B; Wolfert R; Stewart B; Perego R; Hsieh JJ; Weiss RH
Cancer Res; 2015 Jun; 75(12):2541-52. PubMed ID: 25952651
[TBL] [Abstract][Full Text] [Related]
33. LC-MS-Based Plasma Metabolomics and Lipidomics Analyses for Differential Diagnosis of Bladder Cancer and Renal Cell Carcinoma.
Liu X; Zhang M; Cheng X; Liu X; Sun H; Guo Z; Li J; Tang X; Wang Z; Sun W; Zhang Y; Ji Z
Front Oncol; 2020; 10():717. PubMed ID: 32500026
[TBL] [Abstract][Full Text] [Related]
34. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
Tickoo SK; dePeralta-Venturina MN; Harik LR; Worcester HD; Salama ME; Young AN; Moch H; Amin MB
Am J Surg Pathol; 2006 Feb; 30(2):141-53. PubMed ID: 16434887
[TBL] [Abstract][Full Text] [Related]
35. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
[TBL] [Abstract][Full Text] [Related]
36. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.
Ganti S; Taylor SL; Abu Aboud O; Yang J; Evans C; Osier MV; Alexander DC; Kim K; Weiss RH
Cancer Res; 2012 Jul; 72(14):3471-9. PubMed ID: 22628425
[TBL] [Abstract][Full Text] [Related]
37. Predictive model for recurrence of renal cell carcinoma by comparing pre- and postoperative urinary metabolite concentrations.
Morozumi K; Kawasaki Y; Maekawa M; Takasaki S; Sato T; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2022 Jan; 113(1):182-194. PubMed ID: 34710258
[TBL] [Abstract][Full Text] [Related]
38. [Urinary metabolomics study of renal cell carcinoma based on gas chromatography-mass spectrometry].
Zhang L; Li L; Kong H; Zeng F
Nan Fang Yi Ke Da Xue Xue Bao; 2015 May; 35(5):763-6. PubMed ID: 26018279
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.
Huynh MJ; Gusev A; Palmas F; Vandergrift L; Berker Y; Wu CL; Wu S; Cheng LL; Feldman AS
Urol Oncol; 2023 Nov; 41(11):459.e9-459.e16. PubMed ID: 37863744
[TBL] [Abstract][Full Text] [Related]
40. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]